Актуальные новости по всему миру, связанные с биткойнами, Ethereum, крипто, блокчейнами, технологиями, экономикой. Обновляется каждую минуту. Доступно на всех языках.
Размер текста Pfizer’s acquisition of cancer-focused biotech Seagen would be its biggest since 2009. Анжела Вайс / AFP через Getty Images Фармацевтический гигант Pfizer has priced the $31 billion debt offering it will use to fund its big bet on Сиген , the biotech group it agreed to acquire in what would be its biggest takeover since 2009. Pfizer (ticker: PFE) announced pricing Tuesday for eight tranches of notes—maturing between 2025 and 2063, with each tranche worth $3 billion to $6 billion—to fund its acquisition of Сиген (SGEN). The yields on the notes, which will be issued by a wholly owned investment subsidiary and fully guaranteed on a senior unsecured basis by Pfizer, range from 4.45% for the 2026 and 2028 tranche to 5.34% for the 2063 tranche.The company expects the offering to close on May 19.The pharma titan announced that it would buy the cancer-focused biotech in March in a cash deal worth $43 billion—but, as Баррон has reported, the deal faces risks, including from an increasingly tough regulatory backdrop for healthcare deals. Other than any issuance of 10-year and 30-year notes, the debt is expected to be subject to a special mandatory redemption at 101% of the aggregate principal under certain circumstances if the merger is terminated or doesn’t close by an agreed-to date.Напишите Джеку Дентону по адресу [электронная почта защищена]
Анжела Вайс / AFP через Getty Images
Фармацевтический гигант
Pfizer has priced the $31 billion debt offering it will use to fund its big bet on
Сиген , the biotech group it agreed to acquire in what would be its biggest takeover since 2009.
Pfizer (ticker: PFE) announced pricing Tuesday for eight tranches of notes—maturing between 2025 and 2063, with each tranche worth $3 billion to $6 billion—to fund its acquisition of
Сиген (SGEN). The yields on the notes, which will be issued by a wholly owned investment subsidiary and fully guaranteed on a senior unsecured basis by Pfizer, range from 4.45% for the 2026 and 2028 tranche to 5.34% for the 2063 tranche.
The company expects the offering to close on May 19.
The pharma titan announced that it would buy the cancer-focused biotech in March in a cash deal worth $43 billion—but, as Баррон has reported, the deal faces risks, including from an increasingly tough regulatory backdrop for healthcare deals.
Other than any issuance of 10-year and 30-year notes, the debt is expected to be subject to a special mandatory redemption at 101% of the aggregate principal under certain circumstances if the merger is terminated or doesn’t close by an agreed-to date.
Напишите Джеку Дентону по адресу [электронная почта защищена]
Source: https://www.barrons.com/articles/pfizer-seagen-acquisition-debt-offering-e94e7fd3?siteid=yhoof2&yptr=yahoo